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Abstract
Background:  In Thailand, South Africa and Zanzibar, a decrease in malaria morbidity was
observed following the introduction of artemisinin-based combination therapy (ACT). In Senegal,
therapeutic trials supervised the in vivo efficacy of artesunate plus amodiaquine from 1999 to 2005
at the M'lomp village dispensary. The trends in malaria morbidity in this village were evaluated from
2000 to 2002.
Methods: Each year, between July and December inclusive, fevers treated with antimalarials and
slide-proven, uncomplicated malaria cases were collected from dispensary health records. Data
were also collected in 1998, just prior to ACT introduction. Pearson's chi square tests and Student
tests were used to compare two percentages or two means respectively (α = 0.05).
Results: Between 1998 and 2002, the total number of fevers treated with antimalarials and their
repetitiveness progressively decreased: From 2824 to 945 fevers and from 17.6% to 9.7% (RR1998–
2002 = 0.55; [0.44–0.69]; p < 0.0001) respectively. Considering uncomplicated malaria cases only, a
decrease was observed in their total number between 2001 and 2002, from 953 to 570 cases. The
incidence rate and repetitiveness also decreased. The incidence rate fell from 46.1% in 2001 to
37.5% in 2002 (p < 0.0001) and the repetitiveness decreased from 13.0% in 2000 to 6.6% in 2002
(RR2000–2002 = 0.51; [0.35–0.72]; p = 0.0001).
Conclusion: The percentage of uncomplicated malaria cases treated with ACT increased, from
18.9% in 2000 to 64.0% in 2002, making it tempting to conclude an impact on malaria morbidity.
Nonetheless, the decline in incidence rate of uncomplicated malaria was slight and a lower
recorded rainfall was reported in 2002 which could also explain this decline. The context in which
ACT is introduced affects the impact on malaria morbidity. In M'lomp, in contrast to studies in
Thailand, South Africa and Zanzibar, ACT coverage of malaria cases was low and no vector control
measure was deployed. Moreover, the malaria transmission level is higher. In sub-Saharan
countries, in order to optimize the impact on malaria morbidity, ACT deployment must be
supported, on the one hand, by a strengthening of public health system to ensure a high ACT
coverage and, on the other hand, by others measures, such vector control measures.
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Background
Since 2001, in the face of the extension of Plasmodium fal-
ciparum resistance to commonly used antimalarials, the
WHO has advocated the adoption of artemisinin-based
combination therapy (ACT) for treating uncomplicated
malaria [1]. The use of ACT is motivated firstly by its high
efficacy [2,3]. Moreover, the combination of two antima-
larials, with independent modes of action reduces the risk
of emergence of drug resistances [4]. Lastly, artemisinin
derivates reduce gametocyte carriage and could, therefore,
decrease malaria transmission and morbidity [5,6]. In
camps for displaced persons on the north-western border
of Thailand, a 67% reduction in the incidence of malaria
was observed in 1997, following of four years use of
artesunate plus mefloquine (AS+MQ) [7]. In the north-
western Tak province of Thailand, a 60% reduction in the
incidence of malaria was reported in 2003, two years fol-
lowing the introduction of AS+MQ [8]. In KwaZulu-Natal
province of South Africa, the total annual number of out-
patient malaria cases at four health facilities fell by nearly
100% in 2003, three years after the deployment of arte-
mether/lumefantrine (AM/LUM) [9]. Lastly, in North A
District of Zanzibar, the total annual number of outpa-
tient malaria diagnoses decreased by 67% in children
under five years old in 2005, two years after the imple-
mentation of artesunate plus amodiaquine (AS+AQ) [10].
In Senegal, since March 2006, the AS+AQ combination
has been recommended for treating uncomplicated
malaria [11]. From 1999 to 2005, therapeutic trials super-
vised the in vivo efficacy and safety of AS+AQ at four
health facilities in the Oussouye department, particularly
at the M'lomp village dispensary [12,13]. The trends in
malaria morbidity in this village were evaluated from
2000 to 2002 and the possible impact of the introduction
of ACT on these trends was discussed.
Methods
Study site
M'lomp is a village located on the mouth of the Casa-
mance River in south-western Senegal. The climate is char-
acterized by the alternation of two seasons, a rainy season,
from June to October, and a dry season, from November
to May. On January first 2000, 8 000 inhabitants were liv-
ing in M'lomp [14]. The dispensary is able to stain and
read thick blood smears. Malaria is mesoendemic with the
majority of cases occurring between July and December.
In November 1994, the parasite prevalence was 51% in
children less than 15 years old [15]. P. falciparum is the
predominant malaria specie and Anopheles gambiae com-
plex is considered the main vector. The entomological
inoculation rate (EIR) was calculated to be 30 infected
bites per person-year [16]. The first in vivo chloroquine-
resistant cases were detected in 1990 [15]. During the
rainy seasons 1996 and 1997, the parasitological failure
rate by day 14 was as high as 76% [17].
Introduction of ACT at the M'lomp dispensary
In 1999, a comparative therapeutic trial of AS+AQ versus
AQ was carried out to assess the in vivo efficacy and safety
of ACT. From 2000 to 2005, non-comparative trials with
the aim of supervising the efficacy of ACT were conducted.
The detailed protocols used in these trials can be found in
Adjuik et al and Brasseur et al [12,13]. All patients treated
with ACT had slide positive P. falciparum uncomplicated
malaria. The dose regimen was 4 mg/kg of AS and 10 mg/
kg of AQ base per day for three days. All the doses were
administered under clinical supervision. Non-eligible
patients were treated with intramuscular injections of qui-
nine (QN IM) followed by oral chloroquine (CQ) accord-
ing to the usual practice of the dispensary.
Assessment of the malaria morbidity in M'lomp
Malaria morbidity was assessed from July to December
inclusive, in 2000, 2001 and 2002, by an observational
retrospective study on fevers and uncomplicated malaria
cases treated with antimalarials at the dispensary. Data
were also collected in 1998, just prior to ACT introduc-
tion. Data from the year 1999 were not considered in the
study because only children less than 10 years old were
treated with ACT, while from 2000 to 2002 all patients,
independent of their age, were treated. In 2000 and 2001,
ACT was administered for three months each year, from
August to October. In 2002, ACT was administered for five
months, from August to December.
Collecting of malaria morbidity indicators
Two indicators of malaria morbidity were chosen: uncom-
plicated malaria cases and fevers treated with antimalar-
ials. Uncomplicated malaria cases were defined as febrile
patients with a positive thick blood smear. Fevers treated
with antimalarials included uncomplicated malaria cases
and presumed malarial fevers, diagnosed clinically by the
nurse. Data were collected from dispensary health records.
Name, surname, age, sex and address were collected to
identify subjects. Dates of consultation, results of thick
blood smear and antimalarials prescribed were also col-
lected. Fevers with negative thick blood smear were some-
times treated with antimalarials. These fevers were
excluded from the study. Furthermore, recorded rainfalls
were collected from the Departmental Service of Rural
Development of Oussouye, located 9 km from M'lomp.
Measuring repetitiveness of consultation
Repetitiveness was defined as the frequency of consulta-
tion at the dispensary by one subject. It was studied for
each malaria morbidity indicator. Subjects were identified
by their full name, sex, age and address. Patients living
outside of the dispensary's area were excluded from theMalaria Journal 2008, 7:215 http://www.malariajournal.com/content/7/1/215
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study because they were less likely to return for a consul-
tation at the dispensary. Lastly, an investigator coming
from the village and acquainted with the inhabitants val-
idated the identification of subjects.
Statistical analysis
Between July and December inclusive in 2000, 2001 and
2002, for each malaria morbidity indicator the distribu-
tion of prescribed antimalarial treatments, the total
number of cases and their repetitiveness in subjects were
measured. Uncomplicated malaria incidence rates were
calculated as the percentage of positive thick blood
smears. Between July and December inclusive in 1998, the
frequency of thick blood smears in cases of fevers was less
than in 2000–2002, 42.9% in 1998 compared to 74.0% in
2000, 76.7% in 2001 and 80.2% in 2002. Because of this,
the total number of uncomplicated malaria cases and
their repetitiveness in subjects were not studied in 1998.
The analysis of the repetitiveness for each malaria morbid-
ity indicator consisted of the calculation of the mean
number of consultations between July and December
inclusive per subject and the calculation of the percentage
of subjects consulting a second time or more relative to
the total number of subjects having consulted one time.
Moreover, the relative risk for one subject to consult a sec-
ond time for fever treated with antimalarials between July
and December inclusive in 2002 was calculated relative to
the same period in 1998. For uncomplicated malaria, the
relative risk was calculated between July and December
inclusive in 2002 relative to the same period in 2000.
Lastly, the time delays between the first and second con-
sultation were calculated and the mean time delays were
compared from 1998 to 2002 for fever treated with anti-
malarials and from 2000 to 2002 for uncomplicated
malaria.
Statistical analyses were performed using Stata version
6.0. Confidence intervals of percentages and relative risks
were given at 95%. Pearson's chi square tests and Student
tests were used to compare two percentages or two means
respectively (α = 0.05).
Results
Distribution of antimalarial treatments prescribed by the 
dispensary
In 1998, 94.4% of fevers and 100% of uncomplicated
malaria cases were treated with QN IM followed by oral
CQ (Table 1). From 2000 to 2002, the percentage of
uncomplicated malaria cases treated with ACT increased,
from 18.9% in 2000 to 64.0% in 2002. The prescription
of CQ or AQ as monotherapy was rare.
Total number of fevers treated with antimalarials and 
uncomplicated malaria cases
In 1998, 2000 and 2001, the total number of consulta-
tions at the dispensary with any complaint was relatively
stable: 8327, 7868 and 7322 consultations respectively. In
2002, this fell by 36% from the previous year to 4707 con-
sultants. The total number of fevers treated with antima-
larials decreased progressively: From 2824 in 1998 to
2058 in 2000 then 1582 in 2001 and 945 in 2002, corre-
sponding to a 67% reduction between 1998 and 2002
(Figure 1). The total number of uncomplicated malaria
cases was relatively constant in 2000 and 2001 with 1147
cases and 953 cases respectively. In 2002, it fell by 40%
from the previous year to 570 cases.
Incidence rate of uncomplicated malaria
The incidence rate of uncomplicated malaria was 35.8%
in 1998. It increased significantly to 44.2% in 2000 (p <
0.0001) and was not significantly different in 2001,
46.1% (p = 0.23). In 2002, the rate declined to 37.5%,
corresponding to a significant 19% reduction (p <
0.0001) (Figure 1).
Table 1: Distribution of antimalarial treatments prescribed by the dispensary
Total (n) QN IM (n, %) AS+AQ (n, %) CQ or AQ (n, %)
1998 Fevers treated with antimalarials 2 824 2 666 94.4 0 0 158 5.6
Uncomplicated malaria cases 599 599 100 0 0 0 0
2000 Fevers treated with antimalarials 2 058 1 696 82.4 217 10.5 145 7.0
Uncomplicated malaria cases 1 147 877 76.5 217 18.9 53 4.6
2001 Fevers treated with antimalarials 1 582 1 191 75.3 305 19.3 86 5.4
Uncomplicated malaria cases 953 601 63.1 305 32.0 47 4.9
2002 Fevers treated with antimalarials 945 550 58.2 365 38.6 30 3.2
Uncomplicated malaria cases 570 205 36.0 365 64.0 0 0
QN IM: intramuscular injections of Quinine followed by oral Chloroquine (CQ); AS+AQ: Artésunate plus AmodiaquineMalaria Journal 2008, 7:215 http://www.malariajournal.com/content/7/1/215
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Monthly incidence rates of uncomplicated malaria
Because of the very limited number of thick blood smears
made in October 1998 and anomalous incidence rates for
September 2002, these two rates were excluded from the
study (Figure 2). From March to June each year, incidence
rates were at a minimum, between 20% and 30%. From
July, the incidence rate increased progressively to a maxi-
mum at the end of the year. In 1998, the rates from July to
September were lower (between 23.3% and 32.6%), than
in 2000, 2001 and 2002 (between 31.1% and 53.6%).
From October to December in 1998, 2000 and 2001, the
rates were at a maximum, varying between 50.2% and
58.0%. However, in 2002, rates lower than in three previ-
ous years were observed, 39.6% in October, 41.2% in
November and 37.4% in December. Compared to the
same months in 2001, differences were significant (p ≤
0.04).
Repetitiveness of fevers treated with antimalarials
In 1998 and 2000, the mean number of fevers treated with
antimalarials per subject was similar, 1.20 and 1.18
respectively. In 2001 and 2002, it decreased to 1.14 and
1.11 respectively.
The percentage of subjects consulting a second time also
decreased: From 17.6% in 1998 to 9.7% in 2002, corre-
sponding to a significant 45% reduction in the risk to con-
sult a second time (RR1998–2002 = 0.55; [0.44–0.69]; p <
0.0001) (Table 2). Whatever the year, less than 2.5% of
subjects consulted three times.
Repetitiveness of uncomplicated malaria cases
From 2000 to 2002, the mean number of uncomplicated
malaria cases per subject decreased progressively: From
1.15 to 1.11 then 1.07 cases respectively. The percentage
of subjects consulting a second time also decreased: From
13.0% in 2000 to 6.6% in 2002, corresponding to a signi-
ficative 49% reduction in the risk to consult a second time
(RR2000–2002 = 0.51; [0.35–0.72]; p = 0.0001) (Table 2).
Whatever the year, less than 1.9% of subjects consulted
three times.
Time delays between the first and second consultation
From 1998 to 2002, the mean time delay between the first
and second consultation for fever treated with antimalar-
ials changed from 64 ± 38 days to 58 ± 37 days (p = 0.22).
From the first to the second uncomplicated malaria case,
the mean time delay increased from 54 ± 36 days in 2000
to 65 ± 45 days in 2002. However this difference was not
significant (p = 0.13).
Recorded rainfall from 1998 to 2002
From 1998 to 2001, the recorded rainfall increased pro-
gressively: From 1233 mm in 1998 to 1365 mm in 2000
and 1502 mm in 2001. In 2002, the recorded rainfall
Total number of fevers treated with antimalarials – Total  number and incidence rate of uncomplicated malaria cases Figure 1
Total number of fevers treated with antimalarials – 
Total number and incidence rate of uncomplicated 
malaria cases. Blue and green lines represent the total 
number of fever treated with antimalarials (n) and the total 
number of uncomplicated malaria cases (n) respectively. Red 
bars represent the incidence rate of uncomplicated malaria 
(%) (Values are indicated).
Monthly incidence rates of uncomplicated malaria Figure 2
Monthly incidence rates of uncomplicated malaria. 
Green, blue, yellow and red lines represent the monthly inci-
dence rates of uncomplicated malaria (%) between July and 
December in 1998 (October excluded), 2000, 2001 and 2002 
(September excluded) respectively. The black line represents 
the mean monthly incidence rates of uncomplicated malaria 
(%) from 1998 to 2002 (1999 excluded).Malaria Journal 2008, 7:215 http://www.malariajournal.com/content/7/1/215
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decreased to 1062 mm. The years 1998 and 2002 had
lower recorded rainfalls in June and July in comparison
with the years 2000 and 2001.
Discussion
The purpose of this study was to investigate the trend in
malaria morbidity in M'lomp, from 2000 to 2002, during
three years of AS+AQ utilisation. A second objective was
to discuss a possible impact of ACT introduction on
malaria morbidity.
The trend in malaria morbidity and ACT introduction in 
M'lomp
Between 1998 and 2002, both the total number of fevers
treated with antimalarials and their repetitiveness progres-
sively decreased. Considering uncomplicated malaria
cases only, a decrease was observed in their total number
and incidence rate between 2001 and 2002. Their repeti-
tiveness decreased between 2000 and 2002. Furthermore,
the results of non-comparative trials carried out from
2000 to 2005 showed high clinical and parasitological
cure rates at day 28, ranging from 88.5% to 96.7% [13].
The percentage of uncomplicated malaria cases treated
with ACT increased from 2000 to 2002 making it tempt-
ing to conclude an impact on malaria morbidity. How-
ever, a lower recorded rainfall was observed in 2002,
which could also explain this decline. In 1998, prior to the
introduction of ACT, the recorded rainfall was also low
and the incidence rate of uncomplicated malaria was
lower than in 2000 and 2001, years of high rainfalls.
Nonetheless, it is difficult to determine the impact that a
variation in rainfall has on malaria morbidity, especially
since the rainfall was always high, more than one meter in
five months. Moreover, the relationship between rainfall
and transmission is also influenced by rhythm and inten-
sity of the rain [18].
Even if the decline in the incidence rate of uncomplicated
malaria in 2002 was due to ACT administration, this was,
despite its statistical significance, small. Furthermore, the
dispensary frequentation fell by 36% between 2001 and
2002, while during the same time the proportion of con-
sultations due to uncomplicated malaria remained simi-
lar at 13% and 12% respectively. During the transmission
season, malaria constitutes between 30% and 50% of
fever consultations. The remaining 50 to 70% of fevers
resulting in consultation are likely due to respiratory or
gastrointestinal infections. In 2002, a decline in the inci-
dence of fevers of non-malarial origin could therefore
explain the diminution in the numbers of fevers treated
with antimalarials. However, between 1998 and 2001,
whilst the dispensary frequentation was relatively stable
and rainfall had increased, the diminution of fevers
treated with antimalarials had already started. This dimi-
nution could be explained by a reduction in the decision
to treat presumptively. Indeed, from 2000, the presence of
medical staff to conduct therapeutic trials might have
encouraged the nurse to practice more thick blood smears
and to refine his antimalarial prescriptions. This would fit
with the observation that the frequency of blood smears
in patients with fever increased from 42.9% in 1998 to
74.0% in 2000.
In conclusion, the impact of AS+AQ introduction at the
M'lomp dispensary could not be established. Even though
a decline in the malaria morbidity was observed, co-fac-
tors can also explain it. It is interesting to note the decrease
in repetitiveness of uncomplicated malaria cases in 2001,
whereas the recorded rainfall was high and the dispensary
frequentation was similar to 2000. The repetitiveness is a
longitudinal indicator. Its decrease in 2001, while the
incidence rate did not change, well illustrates the supple-
mentary information that it provided in comparison with
a transversal indicator. This type of indicator should be
used more frequently for studying the trends in malaria
morbidity. In three different endemic areas, Trape et al
showed the relation between the total number of attacks
over an entire lifetime and the level of transmission [19].
Table 2: Repetitiveness of fevers treated with antimalarials and uncomplicated malaria cases
Fevers treated with antimalarials Uncomplicated malaria cases
C1 C2 C3 C1 C2 C3
1998 2 346 413 55 - --
17.6; [16.1–19.2] 2.3; [1.8–3.0] - -
2000 1 750 261 38 1 000 130 15
14.9; [13.3–16.7] 2.2; [1.5–3.0] 13.0; [11.0–15.2] 1.5; [0.8–2.5]
2001 1 383 161 34 856 80 16
11.6; [10.0–13.4] 2.5; [1.7–3.4] 9.3; [7.5–11.5] 1.9; [1.1–3.0]
2002 854 83 7 533 35 2
9.7; [7.8–11.9] 0.8; [0.3–1.7] 6.6; [4.6–9.0] 0.4; [0.05–1.3]
C1: Total of subjects having consulted at least one time
C2 and C3: Total and percentage (IC95%) of subjects consulting two and three timesMalaria Journal 2008, 7:215 http://www.malariajournal.com/content/7/1/215
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Impact of ACT in Thailand, South Africa and Zanzibar
The decrease in malaria morbidity observed in Thailand,
South Africa and Zanzibar, has been attributed to early
treatment of malaria cases with ACT [7-10]. In these three
countries, it is certain that the much higher efficacy of
ACT, in comparison to previously used antimalarials, did
reduce the therapeutic failures and caused a rapid decrease
in malaria morbidity. In camps for displaced persons in
Thailand, therapeutic failure rates by day 28 in 1994 were
31% after a high dose of MQ compared to 2% following
AS+MQ treatment [20]. In KwaZulu-Natal province,
South Africa, parasitological failure rates by day 42 were
89% after SP treatment in 2000 in comparison to 1% after
AM/LUM treatment in 2002 [9]. In North A District, Zan-
zibar, therapeutic failure rates among children under five
years old were 60% by day 14 after CQ treatment in 2000
compared to 6% by day 28 after AS+AQ treatment in 2003
[10].
However, in South Africa, Barnes et al concluded that the
impact of ACT could not be seen in the absence of indoor
chemical-residual spraying, reintroduced to the area [9].
In Zanzibar, from February 2006, impregnated bed nets
were distributed to populations at risk. In May 2006, a
94% further reduction of the P. falciparum prevalence was
reported among children under five years old [10]. In
Thailand, vector control measures were already imple-
mented before ACT introduction and therefore did not
contribute to the observed impact [7,8].
Furthermore, all authors agreed that high ACT coverage of
malaria cases was essential to obtain the impact on mor-
bidity and was made possible by high-performance public
health systems, the gratuity of ACT and information cam-
paigns conducted amongst populations [8-10]. The par-
ticular management of camps for displaced persons in
Thailand allowed covering almost 100% of cases [7]. In
the Thai population of Tak province, ACT coverage of
80% was obtained by a considerable strengthening of
health structures [8]. South Africa and Zanzibar also have
high-performance public health systems [9,10]. In Kwa-
Zulu-Natal province, 97% of interviewed subjects
declared seeking treatment at public health facilities in the
event of having fevers [9].
Lastly, all authors considered that the reduction in fre-
quency and density of gametocyte carriage due to artem-
isinin derivates could have contributed to the decrease in
malaria morbidity [5,6,9,10]. In camps for displaced per-
sons in Thailand, the gametocyte prevalence was eleven
times higher in refugees treated with MQ (29.1%) than in
refugees treated with an artemisinin derivative (2.6%) [5].
In Tak province, the gametocyte prevalence was signifi-
cantly lower amongst populations covered by ACT,
between 0.1% and 1.2%, than in Burmese villagers living
on the north-eastern border of Myanmar, between 3.1%
and 10.2% (p < 0.001) [8]. In North A District, Zanzibar,
the gametocyte prevalence among children less than 15
years old was reduced from 1.5% to 0.4% in 2005, two
years after ACT introduction [10]. In Kwa-Zulu Natal
province, South Africa, the gametocyte prevalence was
evaluated at 57% after SP treatment in 2000 compared to
2% after ACT treatment in 2002 [9].
Nonetheless, it is difficult to determine the proportion
attributable to the reduction of gametocyte carriage in the
decrease in malaria morbidity. The use of CQ, which has
no effect on gametocyte carriage, but is associated with
high coverage and early treatment, led to a 50% decrease
in the incidence of presumptive malaria cases between
August 1985 and July 1987 in Katana province of Zaire
[21]. In the Niakhar area of Senegal, a weekly prospective
follow up study of a cohort of 566 children with free
access to health care for three months in the malaria trans-
mission season led, in spite of the high level of CQ resist-
ance, to no return to the dispensary in children who had
receive this treatment and only one case of severe malaria
[22].
Factors limiting the ACT impact in M'lomp
Even though a decline in the incidence rate of uncompli-
cated malaria was observed in M'lomp, it was slight and
the relationship with ACT introduction could not be
firmly established. When considering the studies in Thai-
land, South Africa and Zanzibar, it appears that ACT intro-
duction context determines the impact on malaria
morbidity.
In M'lomp, data collected from dispensary health records
reported frequent usage of QN throughout the study
period. From 2000 to 2004, in vitro susceptibility studies
reported 84% and 90% of P. falciparum sensitive isolates
to QN and artemisinin respectively [23]. Thus, the major-
ity of patients were successfully treated by QN and ACT
introduction did not reduce therapeutic failures in similar
proportions to those observed in Thailand, South Africa
and Zanzibar. It also important to note that, in M'lomp,
no vector control measures were deployed during the
study period. Moreover, the ACT coverage of malaria cases
was low, particularly in 2000 and 2001. Furthermore,
even if the dispensary is well frequented, an important
number of fevers were probably treated at home. In sub-
Saharan countries, self treatments are frequent and the
level of care seeking at public health system is generally
low. In Niakhar, Senegal, from 25% to 50% of fevers are
not treated at the dispensary [24]. In the same way, migra-
tion of populations limited ACT coverage. In 1999, the
census data from M'lomp showed that about 40% of
inhabitants had been non-resident for a part of the year
[14].Malaria Journal 2008, 7:215 http://www.malariajournal.com/content/7/1/215
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Lastly, the malaria transmission level is higher in M'lomp
than in the north-western Thailand and KwaZulu-Natal
province. The EIR was calculated to be 30 infected bites
per person-year in M'lomp [16] compared to less than one
infected bite per person-year in two other cited areas
[6,8,9]. In Nord A District, Zanzibar, the gametocyte prev-
alence in 2003 was evaluated to be 13% among children
from 6 to 14 years old [10], suggesting a lower malaria
transmission level than in M'lomp. The study of the rela-
tionship between malaria transmission and morbidity
showed that the impact of a transmission reduction on
malaria morbidity is significantly higher when the initial
transmission level is low. For EIR between 0.01 to 0.1
infective bites per person-year, the total number of
malaria attacks over an entire lifetime appears directly
proportional to the level of transmission and varies by a
factor of ten, whereas for EIR ranged between 1 to 100, the
total number of attacks over an entire lifetime, which is
always very high, varies at most by a factor of two to three
[19]. Furthermore, in areas of low transmission, malaria
infections are predominantly symptomatic and can there-
fore be detected and treated with ACT [25]. In contrast, in
high malaria transmission areas, asymptomatic infections
are common and these semi-immune individuals act as a
reservoir of gametocytes sustaining the transmission
[26,27].
Finally, it is important to emphasize that in M'lomp ACT
was administered in an experimental context, condition-
ally to a positive thick blood smear and with clinical
supervision of drug intakes. This context allowed a full
compliance of patients to ACT treatment, securing both
schizonticide and gamétocytocide efficacies. In a context
of routine use of ACT, patients' compliance may be
incomplete. In the past, while monotherapy by CQ or SP
were recommended, studies reported partial compliance
[28,29]. The non-compliant patients, even though being
clinically cured, will continue to host parasites and risk
limiting the impact of ACT treatment on both malaria
transmission and morbidity. In Zambia, where 61% of
children less than five years were non-compliant to the
ACT AS+SP [30], a study carried out on the same site and
in children of the same age showed a low cure rate at day
28, 63%. In comparison, the day 28 cure rate in children
for which all doses were clinically supervised was 84%
[31]. To explain these low cure rates, the authors advanced
the high level of resistance to SP and also suggested the
impact of compliance on therapeutic efficacy.
Conclusion
In M'lomp, even though a decline in the incidence rate of
uncomplicated malaria was observed, it was slight and the
impact of ACT introduction could not be clearly estab-
lished. The context in which ACT is introduced affects the
impact on malaria morbidity. In contrast to studies in
Thailand, South Africa and Zanzibar, ACT coverage of
malaria cases was low, no vector control measure was
deployed and the level of malaria transmission is higher.
In sub-Saharan countries, in order to optimize the impact
on malaria morbidity, ACT deployment must be sup-
ported, on the one hand, by a strengthening of public
health system to ensure a high ACT coverage and, on the
other hand, by others measures, such vector control meas-
ures and interventions improving the compliance of
patients to their treatment.
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